Drug Importation Debate: Ilisa Bernstein on the Global Pill

Summary Ilisa Bernstein, a senior Vice President at the American Pharmacists Association, discusses the history and current landscape of drug importation policies with a focus on Florida's program. Safety concerns, supply chain issues, and intellectual property rights are key considerations. The impact on the Canadian drug supply and the transparency of imported drugs for consumers are also discussed. Manufacturer concerns regarding rebates and discounts, as well as potential oversupply and export restrictions, are highlighted. The conversation explores the complexities and concerns surrounding drug importation programs. It discusses the mechanisms that manufacturers may use to control drug importation, such as restricting volume or increasing prices. The potential impact on the drug supply in Canada and the need for policies to protect it are also examined. The logistical challenges at the border and the vulnerabilities in the drug supply chain are highlighted. The importance of maintaining patient confidence in drug quality and the risks associated with personal drug importation are discussed. The conversation concludes by considering alternative solutions to lower drug prices and the inspiration drawn from historical figures. Chapters 00:00 Introduction of Ilisa Bernstein 01:19 Background on Drug Importation 08:21 Safety Concerns 10:04 Supply Chain and Drug Source 14:58 Transparency and IP Issues 20:57 Consumer Transparency and NDC Numbers 21:10 Intellectual Property Concerns 22:59 Challenges and Points of Contention 25:12 Manufacturer Concerns: Rebates and Discounts 28:06 Oversupply and Export Restrictions 29:09 Mechanisms to Control Drug Importation 30:39 Policies to Protect Drug Supply in Canada 31:12 Logistical Challenges at the Border 33:07 Vulnerabilities in the Drug Supply Chain 35:03 Maintaining Patient Confidence in Drug Quality 36:31 Risks Before the Border 38:01 Complexities and Concerns for Community Pharmacists 41:31 The Future of Drug Importation Programs 44:00 The Motivation Behind Drug Importation Programs 46:01 Exploring Other Solutions to Lower Drug Prices 48:19 The Illegality of Personal Drug Importation 49:05 Balancing Cost Savings and Patient Safety 50:02 Inspiration from Historical Figures Resources: Ilisa Bernstein American Pharmacists Association The Partnership for Safe Medicines